Forbes November 8, 2023
The FDA approved Eli Lilly’s injectable weight loss drug today to be marketed as Zepbound. On a chemical level, Zepbound is the same as Mounjaro, Lilly’s GLP-1 agonist already approved to treat diabetes. Zepbound was shown to help people without diabetes lose an average of 18% of their body weight in a late-stage clinical trial. “In light of increasing rates of both obesity and overweight in the United States, today’s approval addresses an unmet medical need,” John Sharretts, who oversees the diabetes and obesity division at the FDA’s Center for Drug Evaluation and Research.
Employers have already been bracing for massive hikes to their employee healthcare costs amid the clamor and growing number of indications for the drugs. Forbes senior...
Today's Sponsors
Today's Sponsor